RU95117043A - STIMBON-4 PRODUCT FOR CORRECTION OF EXCHANGE IN THE CALCIUM PHOSPHATE ORGANISM AND METHOD OF ITS PRODUCTION - Google Patents
STIMBON-4 PRODUCT FOR CORRECTION OF EXCHANGE IN THE CALCIUM PHOSPHATE ORGANISM AND METHOD OF ITS PRODUCTIONInfo
- Publication number
- RU95117043A RU95117043A RU95117043/14A RU95117043A RU95117043A RU 95117043 A RU95117043 A RU 95117043A RU 95117043/14 A RU95117043/14 A RU 95117043/14A RU 95117043 A RU95117043 A RU 95117043A RU 95117043 A RU95117043 A RU 95117043A
- Authority
- RU
- Russia
- Prior art keywords
- correction
- calcium phosphate
- stimbon
- organism
- exchange
- Prior art date
Links
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims 2
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims 2
- 239000001506 calcium phosphate Substances 0.000 title claims 2
- 235000011010 calcium phosphates Nutrition 0.000 title claims 2
- 210000000988 Bone and Bones Anatomy 0.000 claims 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 3
- 239000011707 mineral Substances 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000036740 Metabolism Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000035786 metabolism Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
Claims (1)
Кальций - 31,5 - 32,5
Фосфор - 19,0 - 20,0
Смеси аминокислот - 4,0 - 5,5
2. Способ получения препарата Стимбон-4, отличающийся тем, что при кислотной декальцинации костной ткани раствор костного минерала нейтрализуют, выпавший в осадок минерал отмывают, смешивают с кислотным гидролизатом декальцинированного органического матрикса и высушивают.1. The drug Steambon-4 for the correction of metabolism in the body of calcium phosphate, characterized in that it contains the mineral phase and the hydrolyzate of the organic matrix of bone tissue in the following ratio of components, wt.%:
Calcium - 31.5 - 32.5
Phosphorus - 19.0 - 20.0
Amino Acid Blends - 4.0 - 5.5
2. The method of obtaining the preparation Steambon-4, characterized in that during acid decalcification of the bone tissue, the bone mineral solution is neutralized, the precipitated mineral is washed, mixed with the acid hydrolyzate of the decalcified organic matrix and dried.
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU95117043A true RU95117043A (en) | 1998-02-10 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2358498A1 (en) | The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning | |
| HUP0003999A2 (en) | Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them | |
| CA2286671A1 (en) | Method and formulation for treating vascular disease | |
| CA2257448A1 (en) | Pyridyl alkene- and pyridyl alkine-acid amides as cytostatics and immunosuppressives | |
| CA2446435A1 (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| CA2257133A1 (en) | Human dnase i hyperactive variants | |
| CA2224435A1 (en) | Pyrrolopyrimidines and processes for the preparation thereof | |
| AU5501598A (en) | Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments | |
| BG103474A (en) | Application of derivatives of 7-(2-oxa-5,8-diazobicyclo[4,3,0]non-8-8-yl)-quinoloncarboxylic acid and naphthyridoncarboxylic acid in the therapy of helicobacter pylor infections and the gastroduodenal diseases related to them | |
| CA2280727A1 (en) | Bicyclic amino acids | |
| CA2387787A1 (en) | Nutritional composition for treating inflammatory bowel diseases | |
| AU2002238390A1 (en) | Use of amino acids, amino acid analogues, sugar phosphates and sugar phosphate analogues for treatment of tumors, treatment of sepsis and immunosuppression | |
| NZ243443A (en) | Triazolopyrimidine derivatives, preparation and pharmaceutical compositions thereof | |
| AU2463099A (en) | Gabapentin and its derivatives for the treatment of muscular and skeletal pain | |
| CA2377128A1 (en) | Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise | |
| CA2139385A1 (en) | Products containing g-csf and tnf binding protein | |
| CA2534577A1 (en) | Method for promoting bone growth | |
| GR3026086T3 (en) | L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses | |
| CA2335015A1 (en) | Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug | |
| WO2003008438A3 (en) | Cosmetic or dermatological use of peptides for promoting adhesion between skin cells | |
| HUP0302538A3 (en) | 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them | |
| SG60050A1 (en) | Process for the preparation of enantiomerically pure cyclo-alkanl-indol-and azaindol-and pyrimido(1,2a) indol-carbocylic acids and their activated derivatives | |
| RU95117043A (en) | STIMBON-4 PRODUCT FOR CORRECTION OF EXCHANGE IN THE CALCIUM PHOSPHATE ORGANISM AND METHOD OF ITS PRODUCTION | |
| CA2261259A1 (en) | Alpha-amino acid amides, preparation thereof and the therapeutical use thereof | |
| AU5780398A (en) | Pharmaceutical composition for treatment of heart disease based on cardiac hypertrophy |